Kimberley Philbey-Allen

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Effects of cladribine on intrathecal and peripheral B and plasma cells.

Effects of cladribine on intrathecal and peripheral B and plasma cells.

Journal: Clinical and experimental immunology
Published: September 04, 2024

Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis.

Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis.

Journal: Neurology. Clinical practice
Published: May 16, 2023

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

Journal: Therapeutic advances in neurological disorders
Published: February 23, 2023

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis.

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: March 13, 2022

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial.

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial.

Journal: Pilot and feasibility studies
Published: November 13, 2021

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Journal: Multiple sclerosis and related disorders
Published: November 03, 2021

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Journal: Therapeutic advances in neurological disorders
Published: July 22, 2021

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: April 27, 2021

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Journal: Multiple sclerosis and related disorders
Published: February 23, 2021

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?

Journal: Frontiers in neurology
Published: March 15, 2020

Severe skin reactions associated with cladribine in people with multiple sclerosis.

Severe skin reactions associated with cladribine in people with multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: December 22, 2019

The impact of social capital on patients with multiple sclerosis.

The impact of social capital on patients with multiple sclerosis.

Journal: Acta neurologica Scandinavica
Published: December 14, 2019
Showing 1-12 of 16

Last Updated: 09/26/2026